Karos Pharmaceuticals, a start-up focused on the selective modulation of peripheral serotonin synthesis, recently reported positive results from its Phase 1 clinical trials evaluating KAR5585, a compound being developed to treat orphan diseases such as pulmonary arterial hypertension (PAH) and carcinoid syndrome. KAR5585 is a first-in-class, selective inhibitor of tryptophan hydroxylase…
Bayer and the Canadian Vascular Network (CVN) recently announced the winners of a joint research fellowship that provides recognition and financial support to outstanding Canadian physician-researchers with an academic interest in pulmonary hypertension (PH). The recipients are Dr. Jason Weatherland, a respirologist and clinical assistant professor at the University…
Actelion Pharmaceuticals recently announced that Swissmedic, the Swiss regulatory agency for therapeutic products, has approved the orally active, selective IP prostacyclin-receptor agonist Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH). Uptravi is indicated for the treatment of PAH in patients with advanced functional limitation (NYHA-functional class III/IV) to…
The Pulmonary Hypertension Association (PHA) recently accredited the University of Rochester (UR) Medical Center as a Comprehensive Care Center, recognizing its excellence in research, diagnosis, and clinical care for patients with pulmonary hypertension (PH). The group’s PH Care Centers (PHCC) initiative provides accreditation to centers with expertise in PH, particularly pulmonary arterial…
Eiger BioPharmaceuticals recently reported the dosing of a first patient in its Phase 2 LIBERTY clinical trial, evaluating the effects of ubenimex (Bestatin) as an add-on therapy to current standard of care in patients with pulmonary arterial hypertension (PAH). The study is currently recruiting adult patients with PAH WHO…
Actelion will soon start a Phase 3 clinical trial to assess the effectiveness of Opsumit (macitentan) in delaying the progression of pulmonary arterial hypertension (PAH) in children and adolescents. The long-term trial, called TOMORROW (pediaTric use Of Macitentan tO delay disease pRogRessiOn in PAH Worldwide), will be conducted in more than 20 countries and may lead to the first approved…
PHAware is a project for pulmonary hypertension (PH) patients, loved ones, caregivers, medical professionals and other advocates which has gained great attention from the general public. The initiative was started by the hands of the Van Wormer family and has already become a worldwide network and it is determined to continue working…
The Pulmonary Hypertension Association (PHA) International PH Conference and Scientific Sessions in Dallas, Texas broke an attendance record for the organization’s 25-year history of events for awareness, scientific advancement and strong community connection. Patients, families, caregivers, medical professionals, advocates and others —including celebrities Terrence J and Chloe Temtchine – were among…
The Pulmonary Hypertension Association (PHA) was awarded during its 12th International Conference and Scientific Sessions, in Dallas, two new grants to support its work in pulmonary hypertension (PH). To mark the organization’s 25th anniversary also, PHA also awarded several individuals for advocacy, awareness, volunteerism and fundraising service, at the June 17 –…
Reata Pharmaceuticals has reported positive interim results from the extension Phase 2 LARIAT clinical trial assessing bardoxolone methyl for the treatment of pulmonary arterial hypertension (PAH). The LARIAT trial is assessing the efficacy, safety, and tolerability of bardoxolone methyl compared to a placebo in patients with PAH. The study aims to determine the recommended…
SteadyMed, Ltd., and the Pulmonary Hypertension Association (PHA) recently launched a new campaign, called PHenomenal, offering patients with pulmonary hypertension (PH) and their loved ones a social media outlet through which to share photos and videos that highlight how fascinating and inspirational they are as people. “My patients with PH continually impress me…
Bellerophon Therapeutics, Inc., announced the enrollment of the first patient with pulmonary arterial hypertension (PAH) in its Phase 3 INOvation-1 clinical study, assessing the efficacy and safety of the next-generation INOpulse delivery system. The portable device is designed to continuously administer inhaled nitric oxide (iNO) to ambulatory patients using a carefully controlled,…
Get regular updates to your inbox.